Long-term cohort data suggests that patients using GLP-1 agonists plus metformin experience sustained weight reduction and lower diabetes progression rates compared to historical control groups on metformin alone
It does not diagnose, treat, cure, or prevent any disease, and it is not a substitute for medical care
Future medicinal chemistry efforts may yield next-generation compounds with enhanced properties, including improved tissue selectivity, modified pharmacokinetics, or additional mechanistic activities that complement NNMT inhibition
Expected 12-month results include 15 to 20% body weight loss (65 to 100+ pounds for a 400-pound person), 6 to 10 inch waist circumference reduction, transformative improvement in daily functional capacity, and resolution or significant improvement of multiple obesity-related conditions